Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact

This article was originally published in The Pink Sheet Daily

Executive Summary

Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.

You may also be interested in...

Deals Of The Week: Abbott/Reata, Bristol-Myers Squibb/Simcere, Intarcia/Quintiles

Abbott sends another financial record tumbling as it pays an all-time high $400 million upfront for preclinical AIM compounds from Reata.

Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast

With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.

Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas

Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That’s the strategy management laid out for investors during an R&D day in New York April 8.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts